

Case study

Protein A resin screening for IgG₁

INTRODUCTION

An emerging biotech company providing clinical research, R&D and one-stop production services wanted to improve overall mAb process economics by using a high-capacity Protein A resin to achieve the target product profile.

CHALLENGE

Hoping to achieve a higher dynamic binding capacity, the customer decided to screen a high-capacity protein A resin that could remove process- and product-related impurities to achieve the target product profile.



AVANTOR SOLUTION

Toward this goal, the customer requested a sample of PROchievA™ so that they could perform a screening study. Avantor delivered the sample along with quality and regulatory documentation and guaranteed supply, regulatory support, reliability and competitive pricing.

RESULT – VALUE TO CUSTOMER

In the screening study, PROchievA™ demonstrated the best impurity Host Cell Protein (HCP) clearance capability and 20-50% higher DBC compared to competitors' resins.

CUSTOMER BENEFIT

The customer purchased PROchievA™ bulk materials due to the product's demonstrated efficiency in the affinity capture step.

Protein A resin screening for IgG1

